These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intratumoral immunotherapy: using the tumor as the remedy. Marabelle A; Tselikas L; de Baere T; Houot R Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115 [TBL] [Abstract][Full Text] [Related]
3. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043 [TBL] [Abstract][Full Text] [Related]
4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
5. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164 [TBL] [Abstract][Full Text] [Related]
7. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. Ni K; Luo T; Nash GT; Lin W Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760 [TBL] [Abstract][Full Text] [Related]
8. Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460 [TBL] [Abstract][Full Text] [Related]
9. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
12. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. Ibrahim AM; Wang YH World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622 [TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Blockade in Breast Cancer Therapy. Bu X; Yao Y; Li X Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051 [TBL] [Abstract][Full Text] [Related]
16. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275 [TBL] [Abstract][Full Text] [Related]
17. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Rajani KR; Vile RG Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645 [TBL] [Abstract][Full Text] [Related]